Review of Implant Gonadotrophin-Releasing Hormone Agonist Use: Experience in a Single Academic Center.

BACKGROUND

Gonadotrophin-releasing hormone agonists (GnRHas) are used for puberty suppression in central precocious puberty (CPP) and gender dysphoria (GD). Guidelines on biochemical monitoring are not defined.

OBJECTIVES

The aim of this study was to evaluate the utility of biochemical monitoring of GnRHa therapy in patients with CPP or GD.

METHODS

This is a retrospective chart review of patients 18 years or younger who received GnRHa therapy from January 1, 2018, to March 20, 2021.

RESULTS

A total of 103 patients were evaluated, 43 with CPP and 60 with GD. Using thresholds of basal luteinizing hormone (LH) <2 IU/L and stimulated LH <4 IU/L, biochemical pubertal suppression occurred in all but 2 patients. Basal LH frequently remained above prepubertal range.

CONCLUSIONS

Laboratory assessment for puberty suppression on GnRHa therapy may be unnecessary in CPP and GD patients monitored with physical exams.